Publication - Advice and guidance
Management of threatened miscarriage and recurrent miscarriage: guidance on use of progesterone
The Progesterone Pathway ensures that women who have had at least one previous miscarriage and present with early pregnancy bleeding are offered vaginal micronised progesterone, where it is clinically indicated, and provides guidance on asymptomatic women with four or more previous miscarriages.
Side effects of treatment
Women may experience increased discharge using progesterone pessaries. For information on side effects, cautions, contraindications and interactions please refer to the British National Formulary and Summary of Product Characteristics (SmPC):
Licenced Preparation
Unlicenced Preparations
- Cyclogest 200mg pessaries - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
- Cyclogest 400mg pessaries - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
- Utrogestan Vaginal 200mg Capsules - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
- Progesterone | Drugs | BNF | NICE
Please ensure that you have checked for any allergies or ingredients that are not suitable for some patients.